BioInvent International AB Market Cap ($38.45 Million)
Market Cap & Net Worth: BioInvent International AB (BINV)
BioInvent International AB market cap. BioInvent International AB (ST:BINV) has a market capitalization of $38.45 Million (Skr357.32 Million) as of November 1, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #22679 globally and #426 in its home market, demonstrating a -73.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioInvent International AB's stock price Skr5.43 by its total outstanding shares 65804362 (65.80 Million). Also see BioInvent International AB operating cash flow efficiency for how efficiently the company converts equity into cash flow.
BioInvent International AB Market Cap History (2015–2026)
BioInvent International AB market cap history from 2015 to 2026. Data shows change from $608.73 Million to $38.45 Million (-19.76% CAGR). Check today's stock price for BioInvent International AB for real-time trading data and today's change.
BioInvent International AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioInvent International AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BioInvent International AB (BINV) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.10x
BioInvent International AB's market cap is 6.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $608.73 Million | $15.93 Million | -$90.68 Million | 38.22x | N/A |
| 2016 | $532.54 Million | $71.28 Million | -$62.59 Million | 7.47x | N/A |
| 2017 | $359.07 Million | $45.01 Million | -$100.53 Million | 7.98x | N/A |
| 2018 | $329.93 Million | $38.55 Million | -$123.16 Million | 8.56x | N/A |
| 2019 | $212.55 Million | $93.74 Million | -$139.12 Million | 2.27x | N/A |
| 2020 | $325.05 Million | $147.37 Million | -$76.67 Million | 2.21x | N/A |
| 2021 | $327.17 Million | $19.38 Million | -$278.96 Million | 16.88x | N/A |
| 2022 | $226.97 Million | $326.13 Million | -$34.09 Million | 0.70x | N/A |
| 2023 | $134.27 Million | $71.46 Million | -$330.30 Million | 1.88x | N/A |
| 2024 | $272.64 Million | $44.69 Million | -$429.38 Million | 6.10x | N/A |
Competitor Companies of BINV by Market Capitalization
Companies near BioInvent International AB in the global market cap rankings as of November 1, 2026. Also see BINV asset base for a full breakdown of the balance sheet.
Key companies related to BioInvent International AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of BioInvent International AB (2015–2026)
Market capitalization of BioInvent International AB from 2015 to today. Between 2015 and today, BioInvent International AB's market cap moved from $608.73 Million to $ 38.45 Million, with a yearly change of -19.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr38.45 Million | -81.53% |
| 2025 | Skr208.20 Million | -23.64% |
| 2024 | Skr272.64 Million | +103.06% |
| 2023 | Skr134.27 Million | -40.84% |
| 2022 | Skr226.97 Million | -30.63% |
| 2021 | Skr327.17 Million | +0.65% |
| 2020 | Skr325.05 Million | +52.93% |
| 2019 | Skr212.55 Million | -35.58% |
| 2018 | Skr329.93 Million | -8.12% |
| 2017 | Skr359.07 Million | -32.57% |
| 2016 | Skr532.54 Million | -12.52% |
| 2015 | Skr608.73 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of BioInvent International AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.45 Million USD |
| MoneyControl | $38.45 Million USD |
| MarketWatch | $38.45 Million USD |
| marketcap.company | $38.45 Million USD |
| Reuters | $38.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more